News

Toft Group Completes Executive Search for Agendia in Irvine, CA

Executive search firm Toft Group has placed Mr. Christopher Barbazette as North American Commercial Leader at Agendia in Irvine, CA. Most recently, Mr. Barbazette served as Senior Vice President of Global Commercial Operations at Affymetrix in Santa Clara, CA. He earned a Bachelor degree in International Business – Finance from University of San Francisco, CA.

About Agendia

Agendia is a privately held, leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer and colorectal cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include the FDA-cleared MammaPrint® FFPE as well as BluePrint®, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology. These tests can help physicians assess a patient’s individual risk for metastasis – that is, which patients are more sensitive to chemo, hormonal, or combination therapy, and which patients may not require these treatments and which patients may be treated with other, less arduous and costly methods. In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology.

Toft Group Completes Executive Search for Ionetix Corporation in San Francisco, CA

Executive search firm Toft Group has placed Dr. José Zayas as Vice President of Regulatory Affairs and Quality Assurance at Ionetix Corporation in San Francisco, CA. Dr. Zayas most recently served as Director of Quality Assurance at Trelyst in Carpinteria, CA.

About Ionetix Corporation

Ionetix Corporation is engaged in the development, manufacturing and distribution of a novel class of superconductng cyclotrons for the point-of-care production of PET radioisotopes. With their significantly smaller size, lighter weight, lower power requirement and lower price point, these systems offer significant advantages over conventional-design cyclotron technology.